Stock 0LER TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News Teva Pharmaceutical Industries Limited London S.E.

Equities

0LER

US8816242098

Market Closed - London S.E.
Other stock markets
 16:30:00 31/05/2024 BST 		5-day change 1st Jan Change
16.9 USD +3.21% Intraday chart for Teva Pharmaceutical Industries Limited +1.19% +61.95%
05-30 Teva Pharmaceutical Gains FDA Approval for Daily Huntington's Disease Pill MT
05-30 Teva Pharmaceutical Industries Limited Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24?48 mg/day) CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
BU
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
BU
Teva Pharmaceutical Gains FDA Approval for Daily Huntington's Disease Pill
MT
Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)
BU
Teva Pharmaceutical Industries Limited Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24?48 mg/day)
CI
Teva and Alvotech Announce SIMLANDI Injection Now Available in the U.S.
AQ
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
BU
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
AQ
Teva Pharmaceutical Industries Limited and Alvotech Announce SIMLANDI® Injection Now Available in the U.S
CI
Teva Pharmaceutical Industries Insider Sold Shares Worth $470,794, According to a Recent SEC Filing
MT
New EVP, Teva Global Operations appointed
AQ
Teva Pharmaceutical Industries Insider Sold Shares Worth $254,807, According to a Recent SEC Filing
MT
Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations
BU
Teva Pharmaceutical Industries Limited Announces Management Changes, Effective June 3, 2024
CI
Transcript : Teva Pharmaceutical Industries Limited Presents at Bank of America Health Care Conference 2024, May-14-2024 08:40 AM
Piper Sandler Adjusts Price Target on Teva Pharmaceutical Industries to $20 From $19, Maintains Overweight Rating
MT
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-749 as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
AQ
Teva Pharmaceutical Industries : Immediate Report
PU
Sector Update: Health Care Stocks Slipping Wednesday Afternoon
MT
Teva Pharmaceutical Shares Rise After Reporting Higher Q1 Earnings, Revenue; 2024 Guidance Reaffirmed
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TEVA Stock
  4. 0LER Stock
  5. News Teva Pharmaceutical Industries Limited